USD has the FDA and EU has the EMA. I am not sure how EMA interacts with each individual country.
While regulatory agencies may consider data generated from trials in other jurisdictions, they may ask questions about whether those data and conclusions and relevant and generalizable to their patient populations and health care systems.
There are also ethics to consider. Sure it may be cheaper to run trials in developing countries. But at what point does it become exploitative? Keep in mind that we are talking about human experiments, which is very serious business.
While regulatory agencies may consider data generated from trials in other jurisdictions, they may ask questions about whether those data and conclusions and relevant and generalizable to their patient populations and health care systems.
There are also ethics to consider. Sure it may be cheaper to run trials in developing countries. But at what point does it become exploitative? Keep in mind that we are talking about human experiments, which is very serious business.